		PTO/SB/08 Equivalent
	Application No.	10/522,565
INFORMATION DISCLOSURE	Filing Date	June 20, 2005
STATEMENT BY APPLICANT	First Named Inventor	Fernandez, et al.
STATEMENT BY APPLICANT	Art Unit	1654
(Multiple sheets used when necessary)	Examiner	Heard, Thomas Sweency
SHEET 1 OF 1	Attorney Docket No.	DECLE100.001APC

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

	FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
-						
						-
	L .					

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
/TH/		Meyer-Losic, et al., "Improved Therapeutic Efficacy of Doxorubicin through Conjugation with a Novel Peptide Drug Delivery Technology (Vectocell), J. Med. Chem., Vol. 49, pp. 6908-6916, 2006.	

4404038 101207

12/03/2007 Date Considered Examiner Signature /Thomas Heard/

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.